Prognostic factors for patients with hepatic metastases from breast cancer by Wyld, L et al.
Prognostic factors for patients with hepatic metastases from
breast cancer
L Wyld*,1, E Gutteridge
2, SE Pinder
3, JJ James
4, SY Chan
5, KL Cheung
2, JFR Robertson
2 and AJ Evans
4
1Department of Surgical and Anaesthetic Sciences, University of Sheffield, Sheffield S10 2JF, UK;
2Department of Surgery, Nottingham City Hospital,
Hucknall Road, Nottingham NG5 1PB, UK;
3Department of Histopathology, Nottingham City Hospital, Hucknall Road, Nottingham NG5 1PB, UK;
4Department of Radiology, Nottingham City Hospital, Hucknall Road, Nottingham NG5 1PB, UK;
5Department of Clinical Oncology, Nottingham City
Hospital, Hucknall Road, Nottingham NG5 1PB, UK
Median survival from liver metastases secondary to breast cancer is only a few months, with very rare 5-year survival. This study
reviewed 145 patients with liver metastases from breast cancer to determine factors that may influence survival. Data were analysed
using Kaplan–Meier survival curves, univariate and multivariate analysis. Median survival was 4.23 months (range 0.16–51), with a
27.6% 1-year survival. Factors that significantly predicted a poor prognosis on univariate analysis included symptomatic liver disease,
deranged liver function tests, the presence of ascites, histological grade 3 disease at primary presentation, advanced age, oestrogen
receptor (ER) negative tumours, carcinoembryonic antigen of over 1000ngml
 1 and multiple vs single liver metastases. Response to
treatment was also a significant predictor of survival with patients responding to chemo- or endocrine therapy surviving for a median
of 13 and 13.9 months, respectively. Multivariate analysis of pretreatment variables identified a low albumin, advanced age and ER
negativity as independent predictors of poor survival. The time interval between primary and metastatic disease, metastases at
extrahepatic sites, histological subtype and nodal stage at primary presentation did not predict prognosis. Awareness of the
prognostic implications of the above factors may assist in selecting the most appropriate treatment for these patients.
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Liver metastases are found in 6–25% of patients with metastatic
breast cancer (Tampellini et al, 1997). Most authors quote a
median survival of 1–14 months (Jaffe et al, 1968; Zinser et al,
1987; Patanaphan et al, 1988; O’Reilly et al, 1990; Hoe et al, 1991)
which compares unfavourably with metastases at other sites;
isolated soft tissue metastases have a median survival of 50 months
(Tampellini et al, 1997), bone 33–48 months (Sherry et al, 1986)
and pleural disease 6–15 months (Johnson et al, 1998). Only
cerebral metastases confer a worse prognosis with a median
survival of only 4 months (Johnson et al, 1998). Survival may be
prolonged by chemotherapy or endocrine therapy and a small
proportion of patients may survive for 5 years (3%) or even 10
years (1%) with these therapies (Sledge and Miller, 1999). Current
recommendations are that patients with asymptomatic, oestrogen
receptor (ER) positive liver metastases may be treated with
endocrine therapy (Buzdar, 2001). Those with symptomatic
metastases or ER negative tumours are treated with combination
chemotherapy such as FEC (5-fluorouracil, epirubicin and
cyclophosphamide) or CMF (cyclophosphamide, methotrexate, 5-
fluorouracil) (Fossati et al, 1998; Sledge and Miller, 1999). Taxane
chemotherapy may be used in anthracycline-resistant disease
(Hortobagyi et al, 2000). Novel therapies with monoclonal
antibodies such as trastuzumab (for c-erb-B2/Her-2 positive breast
cancers) are also being used often in combination with taxane
chemotherapy (Fournier et al, 2000). Chemotherapy will achieve a
response in 50–80% of patients and survival may be prolonged
(Hortobagyi, 2000). However, the side effects of these agents may
be severe and occasionally result in fatal complications.
There have been few studies of surgical treatment of liver
metastases from breast cancer, either for attempted cure or
debulking. Several studies suggest a small subgroup of patients
may gain a survival advantage from surgery and there are reports
of rare long-term survivors (Pocard et al, 2000; Selzner et al, 2000).
The aim of this study was to identify factors that enable
prediction of those patients unlikely to survive for prolonged
periods, for whom chemotherapy may be of no benefit and impair
their remaining quality of life.
Liver metastases may present asymptomatically during a
metastatic screen, or may present with upper abdominal fullness,
a mass, ascites, jaundice or weight loss (O’Reilly et al, 1990).
Ultrasound or CT scan usually confirms the diagnosis. Liver
function tests are deranged in 92% of patients at presentation with
gamma glutamyl transferase (GGT) and alkaline phosphatase
being the most commonly elevated enzymes. Overt jaundice is less
common (13%) (O’Reilly et al, 1990).
Factors adversely affecting prognosis include: jaundice (Hoe
et al, 1991), deranged liver function tests (Zinser et al, 1987;
O’Reilly et al, 1990), ascites, palpable hepatomegaly (O’Reilly et al,
1990), poor performance status and disease confined to the liver
(Zinser et al, 1987; Hoe et al, 1991). The interval between primary
presentation and metastatic disease is an important predictor of
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ysurvival in bone metastases (Sherry et al, 1986) but may not be
important in liver metastases (O’Reilly et al, 1990). The tumour
marker CA15-3 is often higher in patients who do poorly, but is
not reported to be an independent predictor of survival
(Tampellini et al, 1997). Carcinoembryonic antigen (CEA) has
not been previously studied in this respect although it is
recognised as useful in monitoring disease progression (Cheung
et al, 2000).
The influence of disease pattern, both outside the liver and
within the liver has received little attention. Two studies suggest
that extrahepatic disease may impair survival (Zinser et al, 1987;
Hoe et al, 1991), but there are no data on the prognostic
significance of disease distribution within the liver.
This study has examined the cases of all patients presenting in
the last 5 years to a single breast unit with metastatic breast cancer
involving the liver at metastatic diagnosis. Survival from the time
of metastatic diagnosis was compared with primary disease
information, patient characteristics and pattern of metastatic
disease in an attempt to establish factors predicting outcome. It is
hoped that these prognostic factors may be of benefit in tailoring
treatment to avoid toxicity to patients with only a short life
expectancy for whom palliative support would be most appro-
priate.
MATERIALS AND METHODS
All patients presenting to the Nottingham City Hospital Breast
Unit with liver metastases between January 1997 and January 2002
were studied. Upon diagnosis with metastatic disease, full staging
was performed including blood tests, (liver function tests (LFTs),
full blood count (FBC), erythrocyte sedimentation rate (ESR), CEA
and CA15-3), a liver ultrasound or CT scan, chest X-ray and bone
scan. Liver biopsy was performed only in cases of diagnostic
doubt.
Patients were treated either symptomatically or with endocrine
or chemotherapy. Treatment selection was based on the fitness of
the patient to tolerate chemotherapy, disease symptoms and the
patient’s wishes. During treatment, patients were reviewed
clinically, radiologically and biochemically every 12 weeks or
more frequently during chemotherapy. The UICC criteria were
used to assess response (Hayward et al, 1977). For the purpose of
this analysis, the term ‘responder’ refers to patients experiencing a
documented response for a minimum of 6 months on endocrine
therapy or 3 months on chemotherapy (British Breast Group,
1974). Responders included complete response, partial response
and static disease (Clinical Benefit Rate). Nonresponders included
only patients with documented progressive disease. The maximal
duration of response was noted.
Tumour marker levels (CA15-3 and CEA, either increasing or
decreasing during treatment) were also assessed. Changes in
tumour markers alone were never considered sufficient criteria for
changing therapy which also required either clinical or radiological
confirmation. Once disease progression was confirmed, treatment
was changed and the assessment protocol repeated. The cause of
death was recorded from the case notes.
The time from metastatic diagnosis to death or the time of
analysis was then compared with patient and disease character-
istics to determine prognostic significance. Grade was determined
using the Nottingham System and classified as grade 1, 2 or 3
(Elston and Ellis, 1991). Oestrogen receptor analysis was by
calculation of McCarthy’s Histochemical (H) score (McCarty et al,
1983), with a score of greater than zero being regarded as ER
positive in the metastatic setting. The lymph node stage and the
size of the primary tumour in millimetres were also recorded.
The Nottingham Prognostic Index (NPI, gradeþnodal
statusþ0.2 primary size in cm) (Haybittle et al, 1982) was
calculated for each patient at primary presentation.
The Nottingham Secondary Prognostic Index (Robertson et al,
1992) was calculated to assess whether this was a useful predictor
of outcome when considering a single dominant metastatic site.
This was calculated as follows:
NSPI ¼ 4 Grade þ 6 ER ðPositive ¼ 1; Negative ¼ 0Þ
  0:1 DFI ðmonthsÞ 4 metastatic site score
ð1 ¼ bone only; 2 ¼ Lung only; 3 ¼ Lung þ Bone; 4 ¼ VisceraÞ:
This scoring system is of value in determining prognosis in
patients with metastatic disease at different sites. Patients with a
score of less than 8 are categorised as good prognosis, 8–16.5 as
moderate prognosis and 416.5 as poor prognosis. The score was
calculated for each of the patients in this series and compared with
survival in months.
Analysis was performed using Kaplan–Meier survival curves
with w
2 analysis or Kruskal–Wallis ANOVA plus Mann–Whitney
U testing to compare medians between groups. Multivariate
analysis was performed using pretreatment variables to determine
which factors were independent prognostic factors. Statistical
significance was accepted if Po0.05. All data are represented as the
median plus range.
RESULTS
Overall survival
A total of 506 patients have presented to the Nottingham Breast
Unit over a 5-year period with metastatic breast cancer to different
sites. Of these, 145 were found to have liver metastases at the time
of initial presentation (28.7%). Of these 145 patients, 100 have died
(69%), with a median survival from time of metastatic diagnosis of
4.23 months (range 0.16–51). There were 40 1-year survivors, six
2-year survivors and one 3-year survivor. No patient has so far
survived 5 years in this study group. The median age of the
patients was 61 years (range 24–92).
Characteristics of primary cancer
Of those patients who initially had presented with operable
primary breast cancer (n¼93, 72.1%), the median NPI, at
presentation was 5.13 (range 2.4–7). The remainder of patients
either presented with inoperable locally advanced primary cancer
(n¼21, 16.3%), or the disease was metastatic at presentation
(n¼15, 11.6%). Oestrogen receptor positivity was found in 38.6%
of tumours, 33.1% were ER negative and 28% were ER unknown.
The majority of patients had grade 3 cancers at presentation (grade
3: 50.3%, grade 2: 22.1%, grade 1: 0.7%).
Both the ER status and grade had a significant effect on
prognosis, with ER-positive patients having a median survival of 7
months (0.4–32) and ER-negative 3.65 months (0.16–51). The
grade of tumour had a similar effect with patients with grade 1 or 2
tumours (combined) having a median survival of 6 months (0.7–
51) and those with grade 3 tumours median survivals of 3.53
months (0.16–31). The wide ranges of these subgroups, however,
mean that clinical application is limited.
The median time from primary to metastatic breast cancer
diagnosis was 29 months, (range 0–291 months). This time period
had no prognostic significance.
The Nottingham Secondary Prognostic Index did not predict
survival, with no significant difference between good, moderate
and poor prognostic groups, although a trend for shorter survival
was seen in the poor prognostic group with a median survival of
4.13 months (0.16–51) compared with good and moderate groups
at 8.45 (0.73–26) and 7.15 (0.57–20), respectively. This probably
reflects the heavy weighting of visceral metastases in this scoring
system.
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Most patients had metastatic disease at multiple sites, with only
25.5% having liver metastases alone (Table 1). There was no
difference in survival between patients with metastatic disease
confined to the liver vs disease at more than one site (Table 1).
The pattern of disease within the liver was most commonly
nonconfluent multiple metastases, with single metastasis the next
most frequent pattern and diffuse involvement of the liver
parenchyma seen least frequently (Table 1). The pattern of
metastases within the liver had a significant effect on prognosis
with patients with a single focus within the liver having the
best prognosis and confluent multiple metastases the worst
(Table 1). The median survival of the 6 patients with a single
focus in the liver and no metastatic disease elsewhere was 10.5
months (1.77–26).
Liver function tests
The majority of patients had deranged liver function tests at
presentation (Table 2). The most common abnormality was an
elevated GGT (73.1%), followed by raised alkaline phosphatase
(60%), low albumin (35.2%), elevated alanine amino transferase
(ALT, 33.8%) and serum bilirubin elevation (12.4%). Some of the
patients with alkaline phosphatase elevation had concomitant bone
metastases, which may have contributed to cases where this was
the only abnormal LFT.
Median survivals were compared between patients with normal,
mildly abnormal (any deviation from the normal range) or
markedly abnormal liver function tests. Both mildly and severely
abnormal values were associated with a significantly reduced
median survival (Table 2). The most reliable predictor of poor
prognosis was a serum bilirubin of over 50, which was associated
with a median survival of 0.6 months with no patient surviving
more than 1.57 months, (Figure 1). The next most significant
predictor was a serum albumin of less then 30gdl
 1 with a median
survival of 1.5 months and no patient surviving longer than 5.1
months. For all of the other LFTs, although the median survivals
were significantly reduced, the range of survival included patients
surviving for over 2 years and are therefore not absolute indicators
of poor prognosis.
Tumour markers
Serum tumour markers were elevated above the normal range
(435Uml
 1) in 75.9% for CA15-3 and 44.8% of cases for CEA
(410ngml
 1).
CA15-3 levels were studied at both above and below the normal
range and also above 1000Uml
 1. Although the median survival
suggested a trend for a worse prognosis with higher levels, no
Table 1 Distribution patterns of breast cancer metastases within and
outside the liver and the effect on survival times
Metastatic
distribution
Number
(percentage)
affected
Median
survival+(range)
(months)
Within the liver
Single metastasis 28 (19.3) 10.34 (1.1–51)
Multiple non-confluent metastases 84 (57.9) 4.6 (0.16–30)
a,b
Diffuse parenchymal metastases 12 (8.3) 1.85 (0.16–31)
a
Multiple confluent metastases 22 (15.3) 1.66 (0.16–20)
a
Outside the liver
Liver alone 36 (24.8) 4.97 (0.16–30) NS
Liver and bone 61 (42.1) 3.87 (0.16–51) NS
Liver and lung 34 (23.4) 5.75 (0.16–51) NS
Liver and pleura 24 (16.6) 4.27 (0.7–23) NS
Liver and other
c 40 (27.6) 4.7 (0.16–32) NS
Liver and multiple sites 43 (29.7) 5.1 (0.3–51) NS
Data shown are the median survival times from the date of diagnosis with liver
metastases (plus range). Patients in the site-specific rows may be included in the
multiple sites rows.
aDenotes statistical significance compared with survival for single
metastasis.
bDenotes statistical significance compared with survival for diffuse and
multiple confluent meatastases, Po0.05, Kruskal–Wallis ANOVA and Mann–
Whitney U-test.
cOther metastases include four CNS, two ovarian, 18 with para-
aortic, mediastinal or supracalvicular nodes, nine with ascites, one adrenal, one
endometrial and two cutaneous. NS¼not statistically significant.
Table 2 Biochemical parameters influencing survival times with liver
metastases from breast cancer
Biochemical test
(normal range+units)
Median survival if
normal (months)
Median survival if
abnormal (months)
ALT o50 6.0 (0.16–51) 2.6 (0.16–25)*
(Up to 50IU) n¼87 n¼49
Alkaline phosphatase o1000 5.13 (0.16–51) 1.1 (0.16–25)*
(Up to 300iu) n¼113 n¼22
Alkaline phosphatase o500 6.96 (0.17–51) 1.58 (0.16–31)*
(Up to 300IU) n¼89 n¼46
Albumin o35 7.0 (0.27–51) 2.0 (0.16–27.2)*
(35–45gl
 1) n¼82 n¼51
Albumin o30 5.86 (0.16–51) 1.5 (0.16–5.13)*
(35–45gl
 1) n¼116 n¼20
Bilirubin 450 4.9 (0.16–51) 0.6 (0.16–1.57)*
(o18mmoll
 1) n¼131 n¼6
Bilirubin 420 5.1 (0.16–51) 1.38 (0.16–25)*
(o18mmoll
 1) n¼117 n¼18
GGT 4250 6.0 (0.16–51) 2.67 (0.16–31)*
(Up to 50IU) n¼90 n¼44
CEA 41000 4.9 (0.16–51) 1.035 (0.4–5.1)*
(Up to 10ngml
 1) n¼127 n¼8
CEA410 5.26 (0.16–32) 4.0 (0.16–51) NS
(Up to 10ngml
 1) n¼70 n¼65
CA15-3 435 6 (0.4–32) 4.2 (0.16–51) NS
(Up to 35Uml
 1) n¼26 n¼110
ALT¼alanine amino transferase; GGT¼gamma glutamyl transferase;
CEA¼carcinoembryonic antigen. Data shown are the median survival times from
the date of diagnosis with liver metastases plus the range in brackets. The number of
patients in each group is also shown (n). *Denotes statistical significance, Po0.01.
NS¼not significant.
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Figure 1 Kaplan–Meier cumulative survival plots for survival with liver
metastases according to serum bilirubin level at metastatic diagnosis. Low
bilirubin refers to serum concentration of less than 50mMl
 1. High bilirubin
refers to serum concentration of greater than 50mMl
 1. Po0.0001, (w
2
53.4, 1df).
Liver metastases from breast cancer
L Wyld et al
286
British Journal of Cancer (2003) 89(2), 284–290 & 2003 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
ystatistically significant difference was detected, and therefore
CA15-3 cannot be used to estimate prognosis (Table 2).
Carcinoembryonic antigen (CEA) levels were studied at both
above and below the normal range and also above 1000ngml
 1.A t
a cutoff of 10ngml
 1, the normal upper limit, no useful predictive
value was found. However, if a level of 1000ngml
 1 was used,
median survival was not only dramatically reduced, but the longest
survival was only 5.1 months, which suggests that a serum CEA
level of greater than 1000ngml
 1 may have useful prognostic
implications. However, this factor is of limited value as only eight
patients had CEA elevation of this magnitude (Table 2).
Patient characteristics
In most cases, the liver metastases were asymptomatic at the time
of metastatic diagnosis and were detected by a metastatic screen
when the patient presented with symptomatic metastases else-
where (n¼88, 78.6%). The remainder were symptomatic, present-
ing with epigastric pain or fullness (n¼24, 21.4%). Symptomatic
liver disease carried a worse prognosis than asymptomatic liver
metastases with median survivals of 4.9 (0.16–26) and 9.2 (0.5–51)
months, respectively (Po0.001). Palpable hepatomegaly was
present in only 30 patients (27.3%) but indicated a poor prognosis
(median survival of 5.8 vs 9.1 months, Po0.0004).
The presence of ascites was uncommon (n¼9, 6.2%) but was a
significant predictor of poor prognosis, with a median survival of
0.8 (0.16–8) months vs 5 months (0.16–51) if absent (Po0.003). In
addition, the longest survival with ascites was only 8 months and
therefore this parameter may be clinically useful in making
treatment decisions.
Patient’s age influenced survival; patients over the age of 70
years fared worse than all other age groups (470 years of age:
median survival 3 months (0.16–32), o70 years: median survival
6.0 (0.16–51), Po0.002, Figure 2). However, because of the wide
range, this parameter may not be clinically useful.
Multivariate analysis
Multivariate analysis was performed to assess which of the patient
and disease characteristics (pretreatment) were independent
predictors of survival. Only age, a low serum albumin and ER
status were found to predict independently poor survival. If age
was excluded from the multivariate analysis, grade became
independently important.
Treatment type and response
Complete data on treatment were available on 115 of the 145
patients.
The patient’s clinical status, fitness, hormone receptor status
and age determined the most appropriate treatment. Multiple
different treatments were often given. A total of 13 patients
received palliative treatment from the outset. Chemotherapy,
between one and four different regimens, was given to 58 patients,
often in conjunction with endocrine therapy. Endocrine therapy
was given to 60 patients, of whom 39 had endocrine therapy alone.
The group receiving endocrine therapy was significantly older than
that given chemotherapy with a median age of 75 years for
endocrine therapy (range 45–92) vs 51 years for the chemotherapy
group (range 24–77, Po0.00). Only three patients over the age of
70 years received chemotherapy (aged 70, 71 and 77 years).
Symptomatic therapy only Patients in this group were treated
with analgesia and/or steroids. The median age was 66 years (range
41–87), which was significantly higher than the chemotherapy-
treated group (Po0.002). The median survival for this group
(n¼13) was 0.8 months (0.16–4.2).
Endocrine therapy Of the 60 patients in this group, 39 received
endocrine therapy alone with 21 also having some form of
chemotherapy. Chemotherapy and endocrine therapy were given
sequentially rather than concurrently. Confining analysis to
patients for whom endocrine therapy was the sole treatment, only
six (15.4%) had a response lasting at least 6 months. All of these
patients had ER-positive tumours, which tended to be low grade.
Of all nonresponders to endocrine treatment (including those who
also had chemotherapy, n¼54), 34 were ER positive, 14 were ER
negative and five cases ER unknown. Many patients had several
types of endocrine therapy with a total of 80 courses being
prescribed. Of the 80 courses, only six responded at 6 months
(7.5%, Table 3).
Direct comparison between endocrine- and chemotherapy-
treated patients is not appropriate as patients selected for these
treatments differed in age and fitness. However, endocrine
treatment, if successful, significantly prolonged life. The six
patients responding to endocrine therapy had a median survival
of 13.9 months (range 6–26) compared to 2.6 months (range 0.56–
32) for nonresponders (Po0.0002). The responders had relatively
favourable prognostic features such as normal LFTs, single or
nonconfluent liver metastatic pattern and little or no extrahepatic
metastatic disease.
Chemotherapy A total of 58 patients had chemotherapy,
with a total of 82 courses of various types being given. In
all, 21 patients also had endocrine therapy but only one res-
ponded. No response to chemotherapy was seen in 18 patients
(including two who died after one cycle of treatment, and
two who only had one cycle due to poor tolerance), 10 patients
responded for at least 3 months and 29 responded for at
least 6 months. The response rate (3 or 6 months) per treatment
course was 60 out of 82 courses (73.2%). A total of 22 patients went
on to have two types of chemotherapy, eight had three types and
one patient had four types of chemotherapy. The relative survival
times of these three groups were 4.6 months for nonresponders
(range 1.2–12), 10.23 for 3-month responders (range 4.1–23,
Po0.003) and 13.23 for 6-month responders (range 6–51,
Po0.003, Table 3).
Two deaths were related to chemotherapy: one to zoster
septicaemia and the other to massive pulmonary embolism.
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Figure 2 Kaplan–Meier cumulative survival plots for survival with liver
metastases by age group. Categories refer to age at metastatic diagnosis.
Po0.0001 (w
2 20.8, 4df).
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The cause of death was recorded in 75 of the 100 deceased patients,
although it should be noted that the cause of death recorded in the
notes in patients with known metastatic disease may be unreliable.
In 73 of the 75 cases (97%), carcinomatosis was either the primary
cause (64 cases) or a significant contributing cause of death (nine
cases). Two patients died as a result of chemotherapy (see above).
Six deaths were contributed to by peptic ulcer disease (haemor-
rhage n¼2, perforation n¼4), often in patients on NSAIDs or
steroids or both.
Cerebral metastases were seen in 16 patients. In four, they
were diagnosed at metastatic presentation. In 12, they were
diagnosed during or after chemotherapy despite a good
response in extracerebral sites. The median survival of patients
with cerebral metastases overall was good from the time of
diagnosis of liver metastases being 9.5 (0.8–27.2) months, but
median survival from the time of diagnosis of cerebral disease was
only 1.25 (0.5–18.1) months, despite treatment with cranial
irradiation and steroids.
Factors not influencing survival
No prognostic significance was found to be attached to the
metastases-free interval, the presence of other metastatic sites
(Table 1), the histological subtype, the nodal stage at presentation,
the Nottingham Prognostic Index (primary) or the presence or
absence of vascular invasion.
DISCUSSION
Liver metastases from breast cancer have a poor prognosis, with a
median survival in this study of only 4.23 months. This is similar
to, or better than, the findings of other published series
(Patanaphan et al, 1988; O’Reilly et al, 1990; Hoe et al, 1991).
Those patients receiving chemotherapy had a relatively good
overall prognosis, with responders surviving for a median of 13
months. Those responding to endocrine therapy (n¼6) fared even
better with a median survival of 13.9 months. It must be
remembered, however, that patients who received chemotherapy
were a selected group with a lower median age and better general
health than the non-chemotherapy-treated group. For example,
only one of the patients presenting with evidence of liver failure
(i.e. serum bilirubin of over 50, palpable hepatomegaly, ascites,
hypoalbuminaemia) received chemotherapy but the patient died
during the first cycle. Most such patients were either treated
palliatively or with endocrine therapy. Endocrine therapy was
seldom effective and of the six patients who responded, all were ER
positive. This is comparable with the response rate quoted by
O’Reilly et al (1990) but lower than the overall response rate of
metastatic disease at other sites of 65% (Buzdar, 2001). It is
disappointing that the response rate has not increased despite the
current availability of an increased range of endocrine therapies.
Patients were often treated with endocrine therapy if they were
unfit for chemotherapy and in the group of 39 patients receiving
endocrine therapy, 29 were over the age of 70 years and, of these,
14 had an albumin of less than 35gdl
 1 at presentation. This may
explain much of the poor performance of endocrine treatment in
this study.
The older age group of patients did significantly worse than the
under 70-year age group. Mortality differences with increasing age
in primary breast cancer patient may be due to death from
comorbid conditions (Yancik et al, 2001), but the breast cancer-
specific mortality also increases with age when metastatic disease
is present (Yancik et al, 1989). This is in agreement with our data,
where cause of death was almost always due to carcinomatosis,
even in the elderly. Treatment practice differed with age, with 56%
(55 out of 98) of the under 70s receiving chemotherapy, but only
6.4% (three out of 47) of the over 70s. Chemotherapy tolerance
may be reduced in the elderly (Walsh et al, 1989) and reduced
renal function may necessitate dosage reduction; this may reduce
toxicity but compromises efficacy, (Gelman and Taylor, 1984).
Despite this, there are reports of successful use of the chemother-
apy in the elderly (Walsh et al, 1989). In view of the poor
endocrine response rates for liver metastases, should we be
exploring chemotherapy strategies for the elderly?
Peptic ulcer disease complications contributed to death in six
cases, all of whom were taking nonsteroidal anti-inflammatory
drugs or steroids. This highlights the need for gastric mucosal
protection in this high-risk group.
Cerebral metastases, after a good extracerebral response to
chemotherapy, were relatively common. The blood–brain barrier
Table 3 Types and responses achieved with different courses of endocrine or chemotherapy
Type of therapy Number of courses Progressive disease Static disease Partial response Complete response
Endocrine therapy Best response achieved for at least 6 months
Anastrazole 29 27 (93) 1 (3.4) 0 1 (3.4)
Tamoxifen 20 17 (85) 2 (10) 1 (5) 0
Anastrazole+
Goserelin 5 5 (100) 0 0 0
Megestrol acetate 17 17 (100) 0 0 0
Exemestane 5 5 (100) 0 0 0
Fulvestrant 2 2 (100) 0 0 0
Ethinyl oestradiol 2 2 (100) 0 0 0
Chemotherapy Best response achieved for at least 3 months
CMF 11 3 (27.3) 4 (36.4) 3 (27.3) 1 (9.1)
Anthracyclin alone 12 5 (41.6) 2 (16.7) 2 (16.7) 3 (25)
Doxorubicin/taxane 8 3 (37.5) 0 3 (37.5) 2 (25)
Taxane alone 8 2 (25) 0 6 (75) 0
CCI 8 2 (25) 3 (37.5) 1 (12.5) 2 (25)
FAC/FEC 27 4 (14.8) 6 (22.2) 13 (48.1) 4 (14.8)
Vinorelbine 2 1 (50) 0 1 (50) 0
Other
a 6 2 (33.3) 0 4 (66.6) 0
Some patients are included more than once Data shown are patient numbers with percentage in brackets. The number of patients in each group is too small for meaningful
statistical analysis. CMF¼cyclophosphamide, 5-fluorouracil, methotrexate; FAC/FEC¼Fluorouracil, cyclophosphamide and either doxorubicin or epirubicin; CCI¼Cell cycle
inhibitor. Taxanes included both docetaxel and paclitaxol.
aOther¼mitozantrone, trastuzumab plus paclitaxol, CMF+doxorubicin, 5-fluorouracil infusion and 3M (mitomycin,
methotrexate and mitozantrone).
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therefore acts as a sanctuary site for metastases (Carey et al, 2001).
Prevention of this problem is difficult. Prophylactic cranial
irradiation might slow down or prevent the development of
cerebral metastases. However, there is a high risk of cognitive
impairment (DeAngelis et al, 1989). In addition, only 11% of
patients developed symptomatic cerebral metastases, which would
not justify widespread use, especially in view of the absence of
proven therapeutic benefit.
With regard to prediction of likely survival from patient and
disease characteristics, it has been shown that liver function test
derangement, of almost any degree, is associated with a poor
outcome (Zinser et al, 1987; O’Reilly et al, 1990). However, the
range of survival reveals that, although the median survivals are
lower with deranged LFTs, there are still patients who survive for
prolonged periods and therefore in most cases no definite
prognostic implications can be derived. However, in the case of
patients with both a low albumin (o30gdl
 1) and a high bilirubin
(450mmoll
 1), denoting the onset of liver failure, the median
survival was only 0.6 months (range 0.16–1.57). In the presence of
these findings, therefore, there is a worse prognosis predictable at
the individual patient level. The presence of ascites has a similarly
poor outlook.
Very little prognostic information can be gained from the
characteristics and stage of the primary tumour in patients with
liver metastases. The only prognostic factors were the grade and
the ER status of the primary tumour, although once again the
range of survival is such that no useful information can be derived
on an individual patient basis to facilitate therapeutic choices.
The occurrence of metastases at sites outside the liver had no
effect on the outcome for the patient, suggesting that liver
metastases are pre-eminent in causing the patient’s death. The
occurrence of cerebral metastases may confer a worse prognosis,
but very few patients had these at the time of metastatic diagnosis
and therefore no statistical effect could be demonstrated.
The pattern of metastatic disease within the liver has prognostic
implications; patients with single metastasis have the best long-
term survival and multiple confluent and diffuse metastases have
the worst outcome. Of the single liver metastasis group, only six
had no evidence of metastatic disease elsewhere at the time of
presentation and one of these had inoperable primary cancer
precluding curative liver surgery. The five potential surgical
candidates had a median survival of 14 months (range 6–26)
with three still living. At present, it is not routine practice to
perform liver resection for breast metastases due to the frequent
coexistence of metastatic disease elsewhere, the generally poor
prognosis and the magnitude of the surgery. There have, however,
been reports of long-term survival in carefully selected patients
after liver resection for metastases from breast cancer (Pocard et al,
2000; Selzner et al, 2000).
Tumour markers are used for the monitoring of metastatic
disease during treatment (Tampellini et al, 1997; Cheung et al,
2000) but have limitations as a prognostic tool at the diagnosis of
metastatic breast cancer. CA15-3 was elevated above normal in
75.9% of patients at metastatic diagnosis, which is in agreement
with other studies (Tampellini et al, 1997). The level of elevation
could not be used to predict survival, however, even when the
analytical cutoff was very high (41000Uml
 1). Carcinoembryonic
antigen was more useful. This marker was elevated above normal
in 44.8% of patients, in agreement with other data for metastatic
breast cancer (Mughal et al, 1983). Mild elevation carried no
prognostic significance. However, when very high (i.e. above
1000ngml
 1), patients did badly, with a median survival of 1
month. The range was also narrow, with the longest survival being
for only 5.1 months, which means that this may be used on an
individual patient basis to predict poor outcome.
In summary, this study has demonstrated that several factors
may be useful in predicting duration of survival for patients with
liver metastases from breast cancer. Of these, the factors carrying
the most ominous implications are those denoting the presence
of liver failure, that is, a low serum albumin, elevated bilirubin
and the presence of ascites. Many other features have a significant
impact on survival (disease distribution within the liver, patient
age and the grade and ER status of the tumour) but, due to the
wide range of survivals within these groups, these values have
little use on an individual patient basis. In terms of the type of
treatment and response, patients who are given symptomatic
treatment survive very poorly, as expected, although this is likely
to represent both the treatment and the nature of the patient and
their disease. Patients who did best were those responding to
chemotherapy and endocrine therapy, in whom survival of several
years was sometimes achieved and this should be a source of
optimism for both patients and doctors as therapies continue to
improve.
REFERENCES
British Breast Group (1974) Assessment of response to treatment in
advanced breast cancer. Lancet ii: 38–39
Buzdar A (2001) Endocrine therapy in the treatment of metastatic breast
cancer. Semin Oncol 28: 291–304
Carey LA, Ewend MG, Sawyer L, Dees EC, Sartor CI, Graham M (2001)
Disproportionate CNS relapse after aggressive neo-adjuvant chemother-
apy. Abstract. San Antonio Breast Meeting. San Antonio
Cheung KL, Graves CRL, Robertson JFR (2000) Tumour marker measure-
ments in the diagnosis and monitoring of breast cancer. Cancer Treat
Rev 26: 91–102
DeAngelis LM, Delattre J-Y, Posner JB (1989) Radiation-induced dementia
in patients cured of brain metastases. Neurology 39: 789–796
Elston CW, Ellis IO (1991) Pathological prognostic factors in breast
cancer. I. The value of histological grade in breast cancer: experience
from a large study with long-term follow-up. Histopathology 19:
403–410
Fossati R, Confalonieri C, Torri V, Ghislandi E, Penna A, Pistotti V, Tinazzi
A, Liberati A (1998) Cytotoxic and hormonal treatment for metastatic
breast cancer: a systematic review of published randomised trials
involving 31,510 women. J Clin Oncol 16: 3439–3460
Fournier M, Esteva FJ, Seidman AD (2000) Trastuzumab in combination
with chemotherapy for the treatment of metastatic breast cancer. Semin
Oncol 27: 38–45
Gelman RS, Taylor SG (1984) Cyclophosphamide, methotrexate and
5-fluorouracil chemotherapy in women more than 65 years old
with advanced breast cancer: the elimination of age trends in
toxicity by using doses based on creatinine clearence. J Clin Oncol 2:
1404–1413
Haybittle JL, Blamey RW, Elston CW, Johnson J, Doyle PJ, Campbell FC,
Nicholson RI, Griffiths K (1982) A prognostic index in primary breast
cancer. Br J Cancer 45: 361–366
Hayward JL, Carbone PP, Heusen JC, Kumaoka S, Segaloff A, Rubens RD
(1977) Assessment of response to therapy in advanced breast cancer.
Cancer 39: 1289–1293
Hoe AL, Royle GT, Taylor I (1991) Breast liver metastases–Incidence,
diagnosis and outcome. J R Soc Med 84: 714–716
Hortobagyi GN (2000) Developments in Chemotherapy of breast cancer.
Cancer 88: 3073–3079
Jaffe BM, Donegan WL, Watson F, Spratt JS (1968) Factors influencing
survival in patients with untreated hepatic metastases. Surg Gynaecol
Obstet 127: 1–11
Johnson KA, Kramer BS, Crane JM (1998) Management of pleural
metastases in breast cancer. In The Breast. Comprehensive
Management of Benign and Malignant Disease, Bland KI,
Copeland EM (eds) pp 1382–1388. Philadelphia: W.B. Saunders
Company
Liver metastases from breast cancer
L Wyld et al
289
British Journal of Cancer (2003) 89(2), 284–290 & 2003 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
yMcCarty KS, Silva JS, Cox EB, Leight GS, Wells SA, McCarty Sr KS (1983)
Relationship of age and menopausal status to oestrogen receptor content
in primary carcinoma of the breast. Ann Surg 197: 123–127
Mughal AW, Hortobagyi GN, Fritsche HA, Buzdar AU, Yap HY,
Blumenschein GR (1983) Serial plasma carcinoembryonic antigen
measurements during treatment of metastatic breast cancer. JAMA 249:
1881–1886
O’Reilly SM, Richards MA, Rubens RD (1990) Liver metastases from breast
cancer: the relationship between clinical, biochemical and pathological
features and survival. Eur J Cancer 26: 574–577
Patanaphan V, Salazar OM, Risco R (1988) Breast cancer: metastatic
patterns and their prognosis. South Med J 81: 1109–1112
Pocard M, Pouillart P, Asselain B, Salmon RJ (2000) Hepatic resection in
metastatic breast cancer: results and prognostic factors. Eur J Surg Oncol
26: 155–159
Robertson JFR, Dixon AR, Nicholson RI, Ellis IO, Elston CW, Blamey RW
(1992) Confirmation of a prognostic index for patients with metastatic
breast cancer treated by endocrine therapy. Breast Cancer Res Treat
22(3): 221–227
Selzner M, Morse MA, Vredenburgh JJ, Meyers WC, Clavien P-A (2000)
Liver metastases from breast cancer: long term survival after curative
resection. Surgery 127: 383–389
Sherry MM, Greco FA, Johnson DH, Hainsworth JD (1986)
Metastatic breast cancer confined to the skeletal system. Am J Med 81:
381–386
Sledge GW, Miller KM (1999) Metastatic breast cancer: the role of
chemotherapy. Semin Oncol 26: 6–10
Tampellini M, Berruti A, Gerbino A, Buniva T, Torta M, Gorzegna G,
Faggiuolo R, Cannone R, Farris A, Destefanis M, Moro G,
Deltetto F, Dogliotti L (1997) Relationship between CA15-3 serum
levels and disease extent in predicting overall survival of breast
cancer patients with newly diagnosed metastatic disease. Br J Cancer
75: 698–702
Walsh SJ, Begg CB, Carbone PP (1989) Cancer chemotherapy in the elderly.
Semin Oncol 16: 66–75
Yancik R, Ries LG, Yates JW (1989) Breast cancer in ageing women. Cancer
63: 976–981
Yancik R, Wesley MN, Ries LAG, Havlik RJ, Edwards BK,
Yates JW (2001) Effect of age and co-morbidity in post meno-
pausal breast cancer patients aged 55 years and older. JAMA 285:
885–892
Zinser JW, Hortobagyi GN, Buzdar AU, Smith TL, Fraschini G (1987)
Clinical course of breast cancer patients with liver metastases. J Clin
Oncol 5: 773–782
Liver metastases from breast cancer
L Wyld et al
290
British Journal of Cancer (2003) 89(2), 284–290 & 2003 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
y